68505-83-9

Upstream product

• 104-92-7 1-bromo-4-methoxy-benzene 
• 563-47-3 3-Chloro-2-methylpropene 
• 7664-93-9 sulfuric acid 
• 7732-18-5 water 
• 144-55-8 sodium hydrogencarbonate 

Downstream Products

• 75097-62-0 2-(2-Methoxy-5-bromophenyl)-2-methyl-1-propyl methylsulphide 
• 108695-30-3 Methyl (E)-p-[2-(2,3-Dihydro-3,3-dimethyl-5-benzofuranyl)propenyl]benzoate 
• 108695-29-0 <1-(2,3-dihydro-3,3-dimethyl-5-benzofuranyl)ethyl>triphenylphosphonium bromide 
• 108695-31-4 (E)-p-[2-(2,3-Dihydro-3,3-dimethyl-5-benzofuranyl)propenyl]benzoic acid 

Relevant academic research and scientific papers

Oxime derivatives for the treatment of dyslipidemia and hypercholesteremia

The present invention relates to compounds of Formula (I) which may be useful in the treatment of diseases, such as, metabolic disorders, dyslipidemia and/or hyperchloesterolemia: 1

N-substituted heterocycles for the treatment of hypercholesteremia, dyslipidemia and other metabolic disorders; cancer, and other diseases

The present invention relates to certain compounds of Formula (I) which can be useful in the treatment of diseases, such as, cancer, metabolic disorders, Type 2 Diabetes, dyslipidemia and/or hyperchloesterolemia:

Heteroarotinoids as anticancer agents

Novel heteroarotinoid compositions characterized by the formulae: STR1 where: X is S or O; OAc is the acetate group STR2 and R is --H, --OH, --OCH3, or --OC2 H5 and includes STR3 for formulae (1) and (2). Such compositions exhibit activity as anticancer agents.

2,3-Dihydro-7-benzofurancarboxylic Acids

The syntheses of a series of title compounds 1 a-f bearing methyl groups in the heterocyclic part were described.Depending on the substitution pattern the Claisen rearrangement (path A) or the methodology of directed lithiations (path B) were used as the

Heteroarotinoid compounds as anticancer agents

Novel heteroarotinoid compositions characterized by the formulae: STR1 where R is H, CH3 or C2 H5 and X is S, S O, O, NCH3, Si(CH3)2, N+ (H)CH3 [Cl- ], N+ (H)CH3 [Br- ] or N+ (alkyl) CH3 [Cl- or Br-) where alkyl is CH3, C2 H5, CH2 =CHCH2 or C6 H5 CH2. Such compositions exhibit activity as anticancer agents.

Heteroarotinoids as anticancer agents

Novel heteroarotinoid compositions characterized by the formulae: STR1 where: X is S or O; OAc is the acetate group STR2 and R is --H, --OH, --OCH3, or --OC2 H5 and includes STR3 for formulae (1) and (2). Such compositions exhibit activity as anticancer agents.

Heteroarotinoids. Synthesis, Characterization, and Biological Activity in Terms of an Assessment of These Systems To Inhibit the Induction of Ornithine Decarboxylase Activity and To Induce Terminal Differentiation of HL-60 Cells

The synthesis of certain heteroarotinoids has been achieved, namely the systems (2E,4E,6E)-3,7-dimethyl-7-(1,2,3,4-tetrahydro-4,4-dimethyl-6-thiochromanyl)-2,4,6-heptatrienoic acid (1a), ethyl (2E,4E,6E)-3,7-dimethyl-7-(1,2,3,4-tetrahydro-4,4-dimethyl-6-thiochromanyl)-2,4,6-heptatrienoate (1b), (2E,4E,6E)-3,7-dimethyl-7-(1,2,3,4-tetrahydro-4,4-dimethyl-6-chromanyl)-2,4,6-heptatrienoic acid (1c), 2-phthalimidoethyl 3,7-dimethyl-7-(1,2,3,4-tetrahydro-4,4-dimethyl-6-thiochromanyl)-2,4,6-heptatrienoate (1d), methyl (E)-p-benzoate (2a), (E)-p-benzyl alcohol (2b), (E)-p-benzonitrile (2c), (E)-p-benzaldehyde (2d), methyl 4-benzoate (3a), and (E)-p-benzoic acid (3b).Characterization via elemental, IR, 1H NMR, and 13C NMR analyses was completed for these heterocycles.The biological activity of these heteroarotinoids was assayed by either the suppression of the 12-O-tetradecanoylphorbol 13-acetate (TPA) induced synthesis of ornithine decarboxylase (ODC) in mouse skin or the induction of differentiation of human (HL-60) promyelocytic cells.In the ODC assay, system 1a-c exhibited strong activity (within 10percent of or less than the control) whereas alcohols 2b and 3a showed good activity (within 50percent of the control) as compared to either 13-cis-retinoic acid or trans-retinoic acid.Moderate activity was observed with 2a and 2b while 1d and 2c were essentially inactive.With the HL-60 assay, 1a and 1c were approximately 2- and 5-fold less active, respectively, than trans-retinoic acid.In contrast, 2a, 3a, and 3b inducted differentiation of only a very small percentage of the cells.Acids 1a and 1c were the most active heteroarotinoids in the two biological assays.Consequently, the presence of the heteroatom does not eradicate the activity of the heteroarotinoids and thus they may have potential as chemotherapeutic agents.

5-Cyano-2,3-dihydrobenzofurans useful as herbicides

The invention provides herbicidally-active 2,3-dihydro-5-cyanobenzofurans of the formula: STR1 (wherein: R1 and R2 together represent =O or R1 represents hydrogen and R2 represents hydrogen, hydroxy, alkoxy, acyloxy, alkoxycarbonyloxy, alkylthiocarbonyloxy, halogen, isothiocyanato, amino, alkylamino, dialkylamino, arylamino, acylamino, alkoxycarbonylamino, alkylthiocarbonylamino, N-bonded heterocyclyl, cyano or alkylthio; R3 and R4 together represent alkylene or each represent hydrogen or alkyl; and R5, R6 and R7, which may be the same or different, each represent hydrogen, halogen, alkyl, alkoxy, acyl or cyano), processes for their preparation and herbicidal compositions containing them.

Herbicidally-active sulphonates

The invention provides herbicidally-active sulphonates of the formula STR1 wherein X represents a group --CHR3 --OR4 and Y represents a group --OR5, or X and Y together represent a group --CHR3 --O-- or a group